Sotagliflozin,
does it really help with Reduction in the composite of cardiovascular death, heart-failure hospitalization, and urgent heart-failure visits after recent worsening heart failure in type 2 diabetes?
research showsSotagliflozin is rated B because it reduced total cardiovascular deaths, heart-failure hospitalizations, and urgent heart-failure visits in patients with type 2 diabetes recently hospitalized for worsening heart failure. In 1,222 SOLOIST-WHF participants, rates were 51.0 versus 76.3 events per 100 patient-years, HR 0.67 (95% CI 0.52 to 0.85). The trial ended early because of lost funding, and cardiovascular death alone was not significant, so the composite benefit cannot be presented as a mortality benefit.
ads claimApproval language or evidence from other SGLT2 inhibitors does not establish that sotagliflozin independently reduces cardiovascular death. The directly supported claim is fewer composite heart-failure events after recent worsening.
Useful facts when choosing a product
- Sotagliflozin is an oral prescription drug that inhibits intestinal SGLT1 and renal SGLT2; it is not the same molecule as selective SGLT2 inhibitors such as empagliflozin or dapagliflozin.
- In SOLOIST-WHF, treatment began before discharge or a median of two days after discharge, distinguishing this setting from stable outpatient treatment.
- The United States INPEFA authorization provides a regulatory indication but does not itself determine the evidence grade.
- Genital mycotic infection, diarrhea, volume depletion, hypotension, and diabetic ketoacidosis can occur; acute illness, fasting, dehydration, and kidney function require attention.
What the research actually shows
Bhatt and colleagues randomized 1,222 SOLOIST-WHF participants to sotagliflozin or placebo. Over a median nine months, total cardiovascular deaths, heart-failure hospitalizations, and urgent visits favored sotagliflozin with HR 0.67. A subsequent total-hospitalization analysis supported a lower heart-failure burden, while early termination and the nonsignificant mortality component remained limitations.
Why this is classified as B (67)
A molecule-specific 1,222-person placebo-controlled trial found HR 0.67 for total cardiovascular deaths, heart-failure hospitalizations, and urgent visits, but funding-related early termination, short follow-up, and nonsignificant cardiovascular death alone yield B with 67 points.
Counterpoint. For high-risk patients with type 2 diabetes immediately after worsening heart failure, sotagliflozin has meaningful add-on evidence. Blood pressure, kidney function, and ketoacidosis risk still require individualized review.
Rejudgment record. Cross-check applied — Accepted the direct molecule-specific placebo-controlled reduction in composite cardiovascular events, but assigned B rather than A because of funding-related early termination, short follow-up, and nonsignificant cardiovascular death alone. At cross-check the score was lowered to 67 for early termination and the nonsignificant CV-death component (grade B retained).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduction in heart-failure hospitalizations and urgent visits | B | Fewer nonfatal heart-failure events drove the total-event composite benefit. |
| Reduction in the cardiovascular death and heart-failure event composite | B | The hazard ratio was 0.67, with early termination and short follow-up limiting certainty. |
| Reduction in cardiovascular death alone | D | The individual component was not statistically significant and is not an established benefit. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Bhatt DL et al.; SOLOIST-WHF Trial Investigators. 2021 | Multicenter double-blind randomized placebo-controlled trial | 1,222 | Sanofi and Lexicon Pharmaceuticals | Total cardiovascular deaths, heart-failure hospitalizations, and urgent visits | 51.0 versus 76.3 events per 100 patient-years; HR 0.67 (95% CI 0.52 to 0.85). Cardiovascular death alone was not significant. | Pivotal direct randomized trial; terminated early |
| Szarek M et al. 2021 | Prespecified total-hospitalization analysis of SOLOIST-WHF | 1,222 | Sanofi and Lexicon Pharmaceuticals | Total heart-failure hospitalizations and death | Sotagliflozin reduced the burden of recurrent heart-failure hospitalizations. | Supportive analysis of recurrent events |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Sotagliflozin x fewer cardiovascular composite events after worsening heart failure — Evidence Grade B·67. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/sotagliflozin-recent-worsening-heart-failure-events/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.